HIND — Vyome Holdings, Inc.
NASDAQ · Healthcare · Biotechnology
$2.17
+$0.01 (+0.45%)
Vyome Holdings, Inc. (HIND) is a biotechnology company listed on NASDAQ. It is led by Venkateswarlu Nelabhotla M.B.A., based in Harvard Square, Cambridge, MA, United States, 02138, with about 9 employees. Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Latest reported HIND revenue for 2025-09-30 was $34.6K. Net income was -$8.6M. Revenue was down 97.2% from 2025-06-30 to 2025-09-30. HIND currently screens at market cap $16.1M.
Use this HIND page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the HIND quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the HIND SEC filings page. Lician reads the product cache first so this HTML stays unique to Vyome Holdings, Inc. even when a live quote feed is slow.
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
HIND Key Statistics
Market Cap
$16.14M
Volume
2,357
Previous Close
$2.23
Day Range
$2.28 – $2.28
P/B Ratio
2.40
EPS
-$13.83
Revenue
$8.01M
Net Income
-$7.13M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-7.7%
Profit Margin
-89.1%
Employees
9
HIND Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $8.01M | $8.68M | $11.24M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.13M | -$11.39M | -$46.21M |
| EPS (Diluted) | -$13.83 | -$110.87 | -$108.90 |
Total Assets
$4.79M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$693.00K
Operating Cash Flow
-$4.43M
Free Cash Flow
$0.00
Vyome Holdings, Inc. Company Information
- Co-Founder, CEO, President & Director
- Venkateswarlu Nelabhotla M.B.A.
- Headquarters
- Harvard Square, Cambridge, MA, United States, 02138
- Website
- www.vyometx.com
- Phone
- 973-832-8147
- IPO / Founded
- 2016-10-06
- Sector
- Healthcare
- Industry
- Biotechnology